Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
September Price Settlement Rate at 73.5%; Low Figure Blamed on Pharmacy Chains
Wholesalers’ value-based price settlement rate for ethical drugs came in at 73.5% at the end of September, down from 78.1% two years earlier, according to the Ministry of Health, Labor and Welfare. The figure, which fell far shy of the…
To read the full story
Related Article
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- CSIMC Continues to Fire Barbs at “Precursor Premium” Despite Industry Appeal
December 10, 2013
- Mr Umeda of PhRMA Opposes Proposal to Revise Foreign Average Price Adjustment Rule
December 10, 2013
- FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
- JGA President Prefers 60% Rule for NHI Generic Prices, Fails to Gain Support on Five Generic Price Ranges
December 9, 2013
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
REGULATORY
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
- MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
- Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…